Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00401570 · ClinicalTrials.gov registry record · Phase 2
A Study of Volociximab in Combination With Gemcitabine in Metastatic Pancreatic Cancer
A Phase 2 study, sponsored by AbbVie (prior sponsor, Abbott).
- Completed
- Registry status
- Phase 2
- Development phase
- 40
- Enrollment target
NCT00401570 is a Phase 2 study that has completed, run by AbbVie (prior sponsor, Abbott). The registered enrollment target is 40 participants.
The verdict
NCT00401570, a Phase 2 study, has completed, sponsored by AbbVie (prior sponsor, Abbott).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 40 participants
- Enrollment target
Study Summary
This clinical trial is being conducted to determine tumor response and preliminary safety of a monoclonal antibody that specifically binds to a cell surface receptor (α5β1 integrin) that is required for the establishment of new blood vessels during tumor growth, a process known as angiogenesis.
Interventions
- DRUG Gemcitabine
- DRUG Volociximab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2005-03 |
| Est. Completion | 2008-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00401570
The ClinicalTrials.gov registry entry for NCT00401570 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AbbVie (prior sponsor, Abbott), which has 88 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Gemcitabine is the first listed.
NCT00401570 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00401570 about?
NCT00401570 is a clinical study titled "A Study of Volociximab in Combination With Gemcitabine in Metastatic Pancreatic Cancer". This clinical trial is being conducted to determine tumor response and preliminary safety of a monoclonal antibody that specifically binds to a cell surface receptor (α5β1 integrin) that is required for the establishment of new blood vessels during tumor growth, a process known as angiogenesis.
What is the current status of trial NCT00401570?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2005-03. Estimated completion is 2008-06.
What interventions are being tested in trial NCT00401570?
The interventions under investigation include: Gemcitabine (DRUG), Volociximab (DRUG).
Who is sponsoring clinical trial NCT00401570?
This trial is sponsored by AbbVie (prior sponsor, Abbott), which has 88 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.